-

12:55:27 AM

ZLAB Stock News

ZLAB - Zai Lab Limited

11/09/21 7:37 AM

Nasdaq : PRTC, KRTX, ZLAB

low float

PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

PureTech Health plc, a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics, Inc., and Zai Lab Limited, announced their entry into an exclusive license agreement for the development, manufacturing, and commercialization of KarXT in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.

RHEA-AI

positive

11/09/21 7:00 AM

Nasdaq : KRTX, ZLAB

Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

Karuna Therapeutics,...

RHEA-AI

positive

11/09/21 7:00 AM

Nasdaq : ZLAB

Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million, up to $152 million in potential near- and long-term development and commercial milestones and other payments, and low-double-digit to high-teens tiered

RHEA-AI

positive

11/04/21 7:30 AM

Nasdaq : ZLAB

conferences

Zai Lab Announces Upcoming Presentations in November Investor Conferences

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming

RHEA-AI

neutral

10/26/21 7:30 AM

Nasdaq : ZLAB

earnings

Zai Lab to Announce Third Quarter 2021 Financial Results

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the third

RHEA-AI

neutral

10/25/21 7:30 AM

Nasdaq : ZLAB

clinical trial

Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab

Zai Lab Limited

RHEA-AI

neutral

10/21/21 3:00 AM

Nasdaq : ZLAB

clinical trial

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that Zai Lab has reported positive topline results from a randomized, double-blind, placebo-controlled Phase 1 b proof-of-concept study of ZL-1102, an anti-IL-17A targeting Humabody ®. Further information can be...

RHEA-AI

very positive

10/20/21 4:05 PM

Nasdaq : ZLAB

clinical trial

ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study

Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in patients with mild-to-moderate chronic plaque psoriasis; consistent improvement was seen over time First study to demonstrate penetration of protein

RHEA-AI

positive

10/19/21 9:00 AM

Nasdaq : ZLAB

clinical trial

Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial

SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients Statistically significant difference in clinical cure at Test of Cure vs. colistin Favorable safety profile with statistically significant reduction in

RHEA-AI

neutral

10/18/21 7:30 AM

Nasdaq : ZLAB

management

Zai Lab Appoints Scott Morrison to its Board of Directors

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has appointed Scott Morrison to its Board of Directors. Mr.

RHEA-AI

very positive

Prev 1 2 3 4 5 6 7 8 9 10 Next

ZLAB Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.zailaboratory.com
Security nameZai Lab Limited - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2022
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressPudong
StateShanghai
CityShanghai
Zip201210
CountryChina (Mainland)

About Zai Lab Limited

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in itsfocus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.